WO2005011666A1 - Stable sustained release oral dosage form of gabapentin - Google Patents

Stable sustained release oral dosage form of gabapentin Download PDF

Info

Publication number
WO2005011666A1
WO2005011666A1 PCT/IB2004/051408 IB2004051408W WO2005011666A1 WO 2005011666 A1 WO2005011666 A1 WO 2005011666A1 IB 2004051408 W IB2004051408 W IB 2004051408W WO 2005011666 A1 WO2005011666 A1 WO 2005011666A1
Authority
WO
WIPO (PCT)
Prior art keywords
gabapentin
sustained release
gum
tablet
release tablet
Prior art date
Application number
PCT/IB2004/051408
Other languages
French (fr)
Inventor
Manish Chawla
Rajeev Singh Raghuvanshi
Ashok Rampal
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2005011666A1 publication Critical patent/WO2005011666A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Definitions

  • the present invention relates to stable sustained release oral dosage forms of gabapentin and methods for making these dosage forms.
  • Gabapentin (l-(aminomethyl)cyclohexaneacetic acid) is a #-amino acid analogue effective in the treatment of epilepsy. Gabapentin is indicated as an adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults with epilepsy. Gabapentin has also been approved for neuropathic pain in some countries.
  • Gabapentin has been reported to convert to a toxic lactam compound during preparation and storage. This lactam formation is also seen in formulations containing gabapentin. The lactam formation in formulation during storage is apparently a result of the catalytic effects of the excipients used. The lactam has toxicity, which exceeds that of gabapentin itself.
  • the lethal dose (LD ) of gabapentin in mice has been reported to be 8,000 mg/kg while that of the corresponding lactam is 300 mg/kg. Consequently, these impurities and the potential formation of such decomposition products during storage of pharmaceutical compositions must be reduced to a minimum for reasons of safety.
  • a stable sustained release tablet prepared from granules.
  • the granules include gabapentin; one or more hydrophilic rate- controlling polymers selected from the group consisting of hydroxypropylcellulose, polyvinylpyrrolidone and its derivatives, and polysaccharide gum; and, optionally, one or more pharmaceutical excipients.
  • Embodiments of the sustained release tablet may include one or more of the following features.
  • the lactam content of the tablet may not exceed 0.6% by weight of gabapentin when stored for three months at 40°C and 75% relative humidity.
  • the tablet may provide therapeutically effective plasma levels of gabapentin for up to about 24 hours.
  • the sustained release tablet may have a dissolution profile measured in a USP type II dissolution apparatus, at 50 rpm, at a temperature of 37 ⁇ 0.5°C in 900ml of 0.06N hydrochloric acid of at least 90% of the gabapentin being released in a time between 4 hours and 12 hours. More particularly, at least 90% of the gabapentin may be released in a time between 8 hours and 12 hours.
  • the gabapentin may make up from about 100 mg to about l,200mg by weight of the tablet.
  • the hydroxypropylcellulose may have a viscosity of between about 7 cps and about 30,000 cps.
  • the hydroxypropylcellulose may have a viscosity of between about 4,000 cps and about 15,000 cps.
  • the polyvinylpyrrolidone derivative may be selected from crospovidone, copolyvidone and physical mixtures of polyvinylpyrrolidone and polyvinylacetate.
  • the polysaccharide gum may be selected from the group consisting of guar gum, gum arabic, xanthan gum, locust bean gum, gum karaya and gum tragacanth or combinations thereof.
  • the pharmaceutical excipients may be selected from diluents, binders, lubricants and glidants.
  • the sustained release tablet may be formulated such that the granules do not contain hydroxymethyl propylcellulose.
  • the sustained release tablet may further include one or more pharmaceutical excipients mixed with the granules.
  • Embodiments of the process may include one or more of the following features.
  • the lactam content of the tablet may not exceed 0.6% by weight of gabapentin when stored for three months at 40°C and 75% relative humidity.
  • the tablet may provide therapeutically effective plasma levels of gabapentin for up to about 24 hours.
  • the sustained release tablet may have a dissolution profile measured in a USP type II dissolution apparatus, at 50 rpm, at a temperature of 37 ⁇ 0.5°C in 900ml of 0.06N hydrochloric acid of at least 90% of the gabapentin being released in a time between 4 hours and 12 hours. More particularly, at least 90% of the gabapentin may be released in a time between 8 hours and 12 hours.
  • the gabapentin may make up between about 100 mg and about 1 ,200 mg by weight of the tablet.
  • the hydroxypropylcellulose may have a viscosity of between about 7 cps and about 30,000 cps.
  • the hydroxypropylcellulose may have a viscosity of between about 4,000 cps and about 15,000 cps.
  • the polyvinylpyrrolidone derivative is selected from crospovidone, copolyvidone and physical mixtures of polyvinylpyrrolidone and polyvinylacetate.
  • the polysaccharide gum is selected from the group consisting of guar gum, gum arabic, xanthan gum, locust bean gum, gum karaya and gum tragacanth or combinations thereof.
  • the other pharmaceutical excipients are selected from diluents, binders, lubricants and glidant.
  • the process may further include granulating one or more pharmaceutical excipients with the mixture of gabapentin and one or more hydrophilic rate-controlling polymers.
  • a method of treating a medical condition includes providing an oral pharmaceutical sustained release tablet prepared from granules comprising gabapentin, one or more hydrophilic rate controlling polymers selected from the group consisting of hydroxypropylcellulose, polyvinylpyrrolidone and its derivatives, and polysaccharide gum and optionally one or more pharmaceutical excipients.
  • Embodiments of the method of treating may include one or more of the following features or those described above.
  • the medical condition may be one or both of epilepsy and neuropathic pain.
  • sustained release gabapentin tablets can be prepared using hydrophilic polymers selected from the group consisting of hydroxypropylcellulose, polyvinylpyrrolidone and its derivatives, and polysaccharide gums and one or more pharmaceutically acceptable excipients.
  • hydrophilic polymers selected from the group consisting of hydroxypropylcellulose, polyvinylpyrrolidone and its derivatives, and polysaccharide gums and one or more pharmaceutically acceptable excipients.
  • these sustained release tablets of gabapentin are believed to be capable of maintaining plasma levels of gabapentin in a therapeutic range over an extended time period for up to about 24 hours. This can be accomplished, for example, by varying the concentration of polymers within the granules and possibly outside the granules.
  • the stability conditions as defined herein include tolerance of ⁇ 2 ° C in temperature and a tolerance of ⁇ 5% in relative humidity.
  • Gabapentin may be present as a free base, hydrated form such as monohydrate or any other pharmaceutically acceptable salts thereof. Gabapentin may comprise from about 100 mg to about 1200 mg by weight of the tablet.
  • Hydroxypropylcellulose as used herein, can be of different viscosity grades such as sold by Aqualon under the brand name of Klucel® and also by Nippon Soda Co. Ltd, Japan. Suitable grades are those having viscosity of from about 7 to about 30,000 cps. Especially suitable among these hydroxypropylcelluloses are those having viscosity of 4000 to about 30,000 cps. Typically the amount of hydroxypropylcellulose can be from about 3% to about 40%, particularly from about 5% to about 30% and more particularly from about 5% to about 25% by weight of granules.
  • Polyvinylpyrrolidone or PVP refers to a polymer containing N-vinylpyrrolidone as the monomeric unit and is known to the pharmaceutical industry under a variety of designations including povidone, polyvidone, polyvidonum, polyvidonum soluble, and poly(l-vinyl-2-pyrrolidone).
  • Cross-linked polyvinylpyrrolidone known as crospovidone available as Kollidon CL and Kollidon CL-M is also included.
  • the polyvinylpyrrolidone derivatives include among others the copolymer of N- vinyl-2-pyrrolidone and vinyl acetate which is known as copolyvidon, copolyvidone, and copolyvidonum.
  • Polyvinylpyrrolidone and polyvinyl acetate are also included. These mixtures can be in a ratio such as, but not limited to, 20:80 (PVP: polyvinylacetate) like Kollidon SR. It is apparent that other derivatives of polyvinylpyrrolidone known to those skilled in the art can also be used. Polyvinylpyrrolidone is available in a wide range of molecular weights. Particularly suitable are grades having molecular weights between about 8,000 to about 1,300,000 such as Plasdone K-90, Plasdone K-90D. Typically the amount of polyvinylpyrrolidone and its derivatives can be from about 3% to about 40%, particularly from about 3% to about 30% by weight of granules.
  • Polysaccharide gums may be selected from the group consisting of guar gum, gum arabic, xanthan gum, locust bean gum, gum karaya and gum tragacanth. Particularly suitable is guar gum. Typically the amount of polysaccharide gum can be from about 3% to about 80%), particularly from about 3% to about 70% and more particularly from about 3% to about 60% by weight of the granules.
  • the other pharmaceutical excipients are selected from the group consisting of diluents, binders, lubricants and glidants.
  • Suitable diluents include powdered sugar, calcium phosphate, calcium sulfate, microcrystalline cellulose, lactose, mannitol, kaolin, dry starch, sorbitol, etc.
  • Suitable binders include polyvinylpyirolidone and its derivatives; xanthan gum, guar gum; cellulose ethers such as carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose (extragranularly only, not intra- granularly), hydroxypropyl cellulose, ethyl cellulose; gelatin, starch and its derivatives.
  • the granulating liquid can be, but is not limited to, water, ethanol, isopropyl alcohol, acetone, dichloromethane and the like.
  • the binder can be dissolved in the granulating liquid and used as a solution.
  • Lubricants can be talc, stearic acid, vegetable oil, calcium stearate, zinc stearate and magnesium stearate and glidants include talc, silicon dioxide and cornstarch.
  • stable gabapentin sustained release tablets may be prepared by
  • [36] Blending gabapentin with hydrophilic rate-controlling polymer(s) like hydroxypropylcellulose, polyvinylpyrrolidone and its derivatives or polysaccharide gum and other pharmaceutical excipients (but not HPMC) in a mixer. 2. Granulating the blend of step (1) with a granulating liquid or a binder solution. 3. Drying and sizing the granules. 4. Mixing the sized granules with other pharmaceutical excipients and compressing into tablet.
  • hydrophilic rate-controlling polymer(s) like hydroxypropylcellulose, polyvinylpyrrolidone and its derivatives or polysaccharide gum and other pharmaceutical excipients (but not HPMC) in a mixer. 2. Granulating the blend of step (1) with a granulating liquid or a binder solution. 3. Drying and sizing the granules. 4. Mixing the sized granules with other pharmaceutical excipients and compressing into tablet.
  • stable gabapentin sustained release tablets may be prepared by following the steps of
  • Tablets can additionally be coated with non-rate-controlling polymer(s) compositions like Opadry® sold by Colorcon to impart aesthetic appeal.
  • a coating may comprise about 2% by weight of the tablet.
  • Stable gabapentin sustained release tablets and process for the preparation thereof described herein is further illustrated by the following examples but these should not be construed as limiting the scope of the invention.

Abstract

The present invention relates to stable sustained release oral dosage form of gabapentin and methods of making these dosage forms. The stable sustained release tablet is prepared from granules. The granules include gabapentin; one or more hydrophilic rate-controlling polymers selected from the group consisting of hydroxypropylcellulose, polyvinylpyrrolidone and its derivatives, and polysaccharide gum; and, optionally, one or more pharmaceutical excipients.

Description

Description STABLE SUSTAINED RELEASE ORAL DOSAGE FORM OF GABAPENTIN Technical Field
[1] The present invention relates to stable sustained release oral dosage forms of gabapentin and methods for making these dosage forms. Background Art
[2] When a drug dosage form is designed for human consumption, it is desired that the drug show its maximum therapeutic efficacy with minimum side effects. Some of the side effects inherent in the drag can only be minimized if not eliminated, by adjusting the dosing regimen or modifying the bioavailability parameters through designing of dosage forms with sustained release of the drug. But if the drug is susceptible to degradation and forms toxic byproducts over time as such, or due to incompatibility with the excipients present in the dosage form, its consumption can be detrimental to the health of the patient. Various pharmacopeias require that dosage forms be free of these toxic degradation products or, if present, should be within safe permissible limits.
[3] Gabapentin (l-(aminomethyl)cyclohexaneacetic acid) is a #-amino acid analogue effective in the treatment of epilepsy. Gabapentin is indicated as an adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults with epilepsy. Gabapentin has also been approved for neuropathic pain in some countries.
[4] Gabapentin has been reported to convert to a toxic lactam compound during preparation and storage. This lactam formation is also seen in formulations containing gabapentin. The lactam formation in formulation during storage is apparently a result of the catalytic effects of the excipients used. The lactam has toxicity, which exceeds that of gabapentin itself. The lethal dose (LD ) of gabapentin in mice has been reported to be 8,000 mg/kg while that of the corresponding lactam is 300 mg/kg. Consequently, these impurities and the potential formation of such decomposition products during storage of pharmaceutical compositions must be reduced to a minimum for reasons of safety.
[5] Considering the instability of gabapentin in the dosage form and its short half life, it would be advantageous to design a sustained release dosage form of gabapentin which is stable on storage, has low lactam content and provides therapeutically effective plasma levels of gabapentin over a prolonged period. These stable sustained release dosage forms of gabapentin would not only provide a safe mode of gabapentin therapy but also would provide other benefits, such as maintaining steady plasma levels of gabapentin and the possibility of reducing the total daily dose and frequency of dosing to once or twice a day. [6] U.S. Patent No. 6,054,482 provides a list of adjuvants which are purported to have no noticeable influence on the stability of gabapentin. This list includes, among others, hydroxypropylmethylcellulose. Further, U.S. Patent Application no. 2003/0100611 discloses gastric retained dosage forms of gabapentin that contain hydrophilic polymers. Exemplary polymers disclosed include high viscosity or high molecular weight hydroxypropylmethylcellulose. As such, the prior art appears to teach that hy- droxypropyl methylcellulose is compatible with gabapentin. Disclosure
[7] Summary of the Invention
[8] In one general aspect there is provided a stable sustained release tablet prepared from granules. The granules include gabapentin; one or more hydrophilic rate- controlling polymers selected from the group consisting of hydroxypropylcellulose, polyvinylpyrrolidone and its derivatives, and polysaccharide gum; and, optionally, one or more pharmaceutical excipients.
[9] Embodiments of the sustained release tablet may include one or more of the following features. For example, the lactam content of the tablet may not exceed 0.6% by weight of gabapentin when stored for three months at 40°C and 75% relative humidity. The tablet may provide therapeutically effective plasma levels of gabapentin for up to about 24 hours. The sustained release tablet may have a dissolution profile measured in a USP type II dissolution apparatus, at 50 rpm, at a temperature of 37±0.5°C in 900ml of 0.06N hydrochloric acid of at least 90% of the gabapentin being released in a time between 4 hours and 12 hours. More particularly, at least 90% of the gabapentin may be released in a time between 8 hours and 12 hours.
[10] The gabapentin may make up from about 100 mg to about l,200mg by weight of the tablet.
[11] The hydroxypropylcellulose may have a viscosity of between about 7 cps and about 30,000 cps. In particular, the hydroxypropylcellulose may have a viscosity of between about 4,000 cps and about 15,000 cps.
[12] The polyvinylpyrrolidone derivative may be selected from crospovidone, copolyvidone and physical mixtures of polyvinylpyrrolidone and polyvinylacetate. The polysaccharide gum may be selected from the group consisting of guar gum, gum arabic, xanthan gum, locust bean gum, gum karaya and gum tragacanth or combinations thereof.
[13] The pharmaceutical excipients may be selected from diluents, binders, lubricants and glidants. The sustained release tablet may be formulated such that the granules do not contain hydroxymethyl propylcellulose. The sustained release tablet may further include one or more pharmaceutical excipients mixed with the granules.
[14] In another general aspect there is provided a process for the preparation of a stable sustained release tablet. The process includes:
[ 15] granulating a mixture of gabapentin and one or more hydrophilic rate-controlling polymers selected from the group consisting of hydroxypropylcellulose; polyvinylpyrrolidone and its derivatives, and polysaccharide gum or combinations thereof with a granulating liquid or a binder solution;
[16] drying the granules;
[17] mixing the dried granules with one or more pharmaceutical excipients to form a blend; and
[ 18] compressing the blend into a tablet.
[19] Embodiments of the process may include one or more of the following features. For example, the lactam content of the tablet may not exceed 0.6% by weight of gabapentin when stored for three months at 40°C and 75% relative humidity. The tablet may provide therapeutically effective plasma levels of gabapentin for up to about 24 hours. The sustained release tablet may have a dissolution profile measured in a USP type II dissolution apparatus, at 50 rpm, at a temperature of 37±0.5°C in 900ml of 0.06N hydrochloric acid of at least 90% of the gabapentin being released in a time between 4 hours and 12 hours. More particularly, at least 90% of the gabapentin may be released in a time between 8 hours and 12 hours.
[20] The gabapentin may make up between about 100 mg and about 1 ,200 mg by weight of the tablet. The hydroxypropylcellulose may have a viscosity of between about 7 cps and about 30,000 cps. In particular, the hydroxypropylcellulose may have a viscosity of between about 4,000 cps and about 15,000 cps.
[21] The polyvinylpyrrolidone derivative is selected from crospovidone, copolyvidone and physical mixtures of polyvinylpyrrolidone and polyvinylacetate. The polysaccharide gum is selected from the group consisting of guar gum, gum arabic, xanthan gum, locust bean gum, gum karaya and gum tragacanth or combinations thereof. The other pharmaceutical excipients are selected from diluents, binders, lubricants and glidant.
[22] The process may further include granulating one or more pharmaceutical excipients with the mixture of gabapentin and one or more hydrophilic rate-controlling polymers.
[23] In another general aspect, there is provided a method of treating a medical condition. The method includes providing an oral pharmaceutical sustained release tablet prepared from granules comprising gabapentin, one or more hydrophilic rate controlling polymers selected from the group consisting of hydroxypropylcellulose, polyvinylpyrrolidone and its derivatives, and polysaccharide gum and optionally one or more pharmaceutical excipients.
[24] Embodiments of the method of treating may include one or more of the following features or those described above. For example, the medical condition may be one or both of epilepsy and neuropathic pain.
[25] The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims. [26] Detailed Description of the Invention
[27] Based on the teaching of the prior art disclosures described above, we prepared gabapentin tablets with high viscosity and high molecular weight hydroxypropyl methylcellulose. However, contrary to the prior art disclosures, these tablets showed an increase in lactam content on storage (see Examples 5 and 6 and Table 4, herein). Because of the finding that high molecular weight or high viscosity hydroxypropyl methylcellulose actually increases the lactam content, we had to carry out laborious investigations to establish which alkyl substituted cellulose material or hydrophilic polymer is actually compatible with gabapentin.
[28] Surprisingly, as a result of these efforts we discovered that stable sustained release gabapentin tablets can be prepared using hydrophilic polymers selected from the group consisting of hydroxypropylcellulose, polyvinylpyrrolidone and its derivatives, and polysaccharide gums and one or more pharmaceutically acceptable excipients. When these sustained release tablets were kept for three months at 40 ° C and 75% relative humidity, the lactam content did not exceed 0.6% by weight of gabapentin. These sustained release tablets of gabapentin are believed to be capable of maintaining plasma levels of gabapentin in a therapeutic range over an extended time period for up to about 24 hours. This can be accomplished, for example, by varying the concentration of polymers within the granules and possibly outside the granules.
[29] The stability conditions as defined herein include tolerance of ± 2 ° C in temperature and a tolerance of ± 5% in relative humidity.
[30] Gabapentin may be present as a free base, hydrated form such as monohydrate or any other pharmaceutically acceptable salts thereof. Gabapentin may comprise from about 100 mg to about 1200 mg by weight of the tablet.
[31] Hydroxypropylcellulose, as used herein, can be of different viscosity grades such as sold by Aqualon under the brand name of Klucel® and also by Nippon Soda Co. Ltd, Japan. Suitable grades are those having viscosity of from about 7 to about 30,000 cps. Especially suitable among these hydroxypropylcelluloses are those having viscosity of 4000 to about 30,000 cps. Typically the amount of hydroxypropylcellulose can be from about 3% to about 40%, particularly from about 5% to about 30% and more particularly from about 5% to about 25% by weight of granules.
[32] Polyvinylpyrrolidone or PVP refers to a polymer containing N-vinylpyrrolidone as the monomeric unit and is known to the pharmaceutical industry under a variety of designations including povidone, polyvidone, polyvidonum, polyvidonum soluble, and poly(l-vinyl-2-pyrrolidone). Cross-linked polyvinylpyrrolidone, known as crospovidone available as Kollidon CL and Kollidon CL-M is also included. The polyvinylpyrrolidone derivatives include among others the copolymer of N- vinyl-2-pyrrolidone and vinyl acetate which is known as copolyvidon, copolyvidone, and copolyvidonum. Physical mixtures of polyvinylpyrrolidone and polyvinyl acetate are also included. These mixtures can be in a ratio such as, but not limited to, 20:80 (PVP: polyvinylacetate) like Kollidon SR. It is apparent that other derivatives of polyvinylpyrrolidone known to those skilled in the art can also be used. Polyvinylpyrrolidone is available in a wide range of molecular weights. Particularly suitable are grades having molecular weights between about 8,000 to about 1,300,000 such as Plasdone K-90, Plasdone K-90D. Typically the amount of polyvinylpyrrolidone and its derivatives can be from about 3% to about 40%, particularly from about 3% to about 30% by weight of granules.
[33] Polysaccharide gums may be selected from the group consisting of guar gum, gum arabic, xanthan gum, locust bean gum, gum karaya and gum tragacanth. Particularly suitable is guar gum. Typically the amount of polysaccharide gum can be from about 3% to about 80%), particularly from about 3% to about 70% and more particularly from about 3% to about 60% by weight of the granules.
[34] The other pharmaceutical excipients are selected from the group consisting of diluents, binders, lubricants and glidants. Suitable diluents include powdered sugar, calcium phosphate, calcium sulfate, microcrystalline cellulose, lactose, mannitol, kaolin, dry starch, sorbitol, etc. Suitable binders include polyvinylpyirolidone and its derivatives; xanthan gum, guar gum; cellulose ethers such as carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose (extragranularly only, not intra- granularly), hydroxypropyl cellulose, ethyl cellulose; gelatin, starch and its derivatives. The granulating liquid can be, but is not limited to, water, ethanol, isopropyl alcohol, acetone, dichloromethane and the like. Alternatively, the binder can be dissolved in the granulating liquid and used as a solution. Lubricants can be talc, stearic acid, vegetable oil, calcium stearate, zinc stearate and magnesium stearate and glidants include talc, silicon dioxide and cornstarch.
[35] In one embodiment, stable gabapentin sustained release tablets may be prepared by
[36] 1. Blending gabapentin with hydrophilic rate-controlling polymer(s) like hydroxypropylcellulose, polyvinylpyrrolidone and its derivatives or polysaccharide gum and other pharmaceutical excipients (but not HPMC) in a mixer. 2. Granulating the blend of step (1) with a granulating liquid or a binder solution. 3. Drying and sizing the granules. 4. Mixing the sized granules with other pharmaceutical excipients and compressing into tablet.
[37] In another embodiment, stable gabapentin sustained release tablets may be prepared by following the steps of
[38] 1. Blending gabapentin with a portion of hydroxypropylcellulose in a mixer. 2. Granulating the blend of step (1) with a solution of remaining portion of hy- droxypropylcellulose in a granulating liquid. 3. Drying and sizing the granules. 4. Mixing the sized granules with other pharmaceutical excipients and compressing into tablet.
[39] Tablets can additionally be coated with non-rate-controlling polymer(s) compositions like Opadry® sold by Colorcon to impart aesthetic appeal. Such a coating may comprise about 2% by weight of the tablet.
[40] Stable gabapentin sustained release tablets and process for the preparation thereof described herein is further illustrated by the following examples but these should not be construed as limiting the scope of the invention.
[41] Preformulation studies [42] In an excipient compatibility study, the compatibility of gabapentin with hydroxypropylcellulose, polyvinylpyrrolidone, copolyvidone, guar gum and hydroxypropyl methylcellulose among other pharmaceutical excipients was determined. Gabapentin was mixed with these polymers and the mixture was granulated with purified water, the granules were dried, sized and compressed to form tablets. The tablets were then kept for three months at 40 ° C and 75% relative humidity in sealed HDPE bottles. The stability data is given below in Table 1.
[43] Table 1 Stability data of preformulation studies [44]
Figure imgf000007_0001
Figure imgf000008_0001
[45] * 2 Months at 40 ° C/75% RH [46] EXAMPLES 1 - 4 [47]
Figure imgf000008_0002
[48] General Procedure: [49] Gabapentin was mixed with a portion of hydroxypropylcellulose and granulated with remaining portion of hydroxypropylcellulose dissolved in purified water. The granules were dried and sized, mixed with mannitol, copolyvidone (Examples 1, 2 and 4), poloxamer, magnesium stearate and talc and compressed to form a tablet. The tablets were then kept for three months at 40 ° C and 75% relative humidity in sealed HDPE bottles. The stability data is given in Table 2 and shows that the formulations are stable.
[50] Table 2 Stability data of the tablets of Examples 1-4 when stored for three months at 40 ° C and 75% relative humidity (RH). [51]
Figure imgf000008_0003
[52] The dissolution profile of tablets of Examples 1-4 measured in a USP type II dissolution apparatus, at 50 rpm, at a temperature of 37±0.5 ° C in 900 ml of 0.06N hydrochloric acid is given below in Table 3. These profiles show complete release of the drug over a time ranging between 4 hours and 12 hours.
[53] Table 3 Dissolution profiles of tablets of examples 1- 4 measured in a USP type II dissolution apparatus, at 50 rpm, at a temperature of 37±0.5 ° C in 900ml of 0.06N hydrochloric acid
[54]
Figure imgf000009_0001
[55] EXAMPLES 5 and 6 [56]
Figure imgf000009_0002
[57] Procedure [58] Gabapentin was mixed with a portion of hydroxypropylmethylcellulose and mannitol and granulated with the remaining portion of hydroxjφropylmethylcellulose dissolved in purified water. The granules were dried and sized, mixed with copolyvidone, poloxamer, magnesium stearate and talc and compressed to form a tablet. These tablets were kept for 3 months at 40 ° C and 75% relative humidity in sealed HDPE bottles. The stability data is given in Table 4.
[59] Table 4 Stability data of tablets of example 5 when stored for three months at 40 ° C and 75% relative humidity (RH). [60]
Figure imgf000010_0001
[61] The data in Table 1 and 4 clearly indicate the incompatibility of Gabapentin with HPMC. [62] While several particular forms of the inventions have been described, it will be apparent that various modifications and combinations of the inventions detailed in the text can be made without departing from the spirit and scope of the inventions. Accordingly, it is not intended that the inventions be limited, except as by the appended claims.

Claims

Claims
[I] A stable sustained release tablet prepared from granules, the granules comprising: gabapentin; one or more hydrophilic rate-controlling polymers selected from the group consisting of hydroxypropylcellulose, polyvinylpyrrolidone and its derivatives, and polysaccharide gum; and optionally one or more pharmaceutical excipients.
[2] The sustained release tablet according to claim 1 wherein the lactam content of the tablet does not exceed 0.6% by weight of gabapentin when stored for three months at 40 ° C and 75% relative humidity.
[3] The sustained release tablet according to claim 1 wherein the tablet provides therapeutically effective plasma levels of gabapentin for up to about 24 hours.
[4] The sustained release tablet according to claim 1 wherein gabapentin comprises from about 100 mg to about 1,200 mg by weight of the tablet.
[5] The sustained release tablet according to claim 1 wherein the hydroxypropylcellulose has a viscosity of between about 7 cps and about 30,000 cps.
[6] The sustained release tablet according to claim 5 wherein the hydroxypropylcellulose has a viscosity of between about 4,000 cps and about 15,000 cps.
[7] The sustained release tablet according to claim 1 wherein the polyvinylpyrrolidone derivative is selected from crospovidone, copolyvidone and physical mixtures of polyvinylpyrrolidone and polyvinylacetate.
[8] The sustained release tablet according to claim 1 wherein the polysaccharide gum is selected from the group consisting of guar gum, gum arabic, xanthan gum, locust bean gum, gum karaya and gum tragacanth or a combinations thereof.
[9] The sustained release tablet according to claim 1 wherein the pharmaceutical excipients are selected from diluents, binders, lubricants and glidant.
[10] The sustained release tablet according to claim 1 wherein the granules do not contain hydroxypropyl methylcellulose.
[I I] The sustained release tablet according to claim 1 wherein the tablet further comprises one or more pharmaceutical excipients mixed with the granules.
[12] The sustained release tablet according to claim 1 wherein the tablet has a dissolution profile measured in a USP type II dissolution apparatus, at 50 rpm, at a temperature of 37±0.5°C in 900ml of 0.06N hydrochloric acid of at least 90% of the gabapentin being released in a time between 4 hours and 12 hours.
[13] The sustained release tablet according to claim 12 wherein at least 90%o of the gabapentin is released in a time between 8 hours and 12 hours.
[14] A process for the preparation of a stable sustained release tablet, the process comprising: granulating a mixture of gabapentin and one or more hydrophilic rate- controlling polymers selected from the group consisting of hydroxypropylcellulose; polyvinylpyrrolidone and its derivatives, and polysaccharide gum or combinations thereof with a granulating liquid or a binder solution; drying the granules; mixing the dried granules with one or more pharmaceutical excipients to form a blend; and compressing the blend into a tablet. [ 15] The process according to claim 14 wherein the lactam content of the tablet does not exceed 0.6% by weight of gabapentin when the tablet is stored for three months at 40 ° C and 75% relative humidity [16] The process according to claim 14 wherein the tablet provides therapeutically effective plasma levels of gabapentin for up to about 24 hours. [17] The process according to claim 14 wherein gabapentin comprises between about 100 mg and about 1,200 mg by weight of the tablet. [18] The process according to claim 14 wherein the hydroxypropylcellulose has a viscosity of between about 7 cps and about 30,000 cps. [19] The process according to claim 17 wherein the hydroxypropylcellulose has a viscosity of between about 4,000 cps and about 15,000 cps. [20] The process according to claim 14 wherein the polyvinylpyrrolidone derivative is selected from crospovidone, copolyvidone and physical mixtures of polyvinylpyrrolidone and polyvinylacetate. [21] The process according to claim 14 wherein the polysaccharide gum is selected from the group consisting of guar gum, gum arabic, xanthan gum, locust bean gum, gum karaya and gum tragacanth or combinations thereof. [22] The process according to claim 14 wherein the other pharmaceutical excipients are selected from diluents, binders, lubricants and glidant. [23] The process according to claim 14 further comprising granulating one or more pharmaceutical excipients with the mixture of gabapentin and one or more hydrophilic rate-controlling polymers. [24] A method of treating a medical condition, the method comprising providing an oral pharmaceutical sustained release tablet prepared from granules comprising gabapentin, one or more hydrophilic rate controlling polymers selected from the group consisting of hydroxypropylcellulose, polyvinylpyrrolidone and its derivatives, and polysaccharide gum and optionally one or more pharmaceutical excipients. [25] The method of treatment according to claim 24 wherein the medical condition comprises one or both of epilepsy and neuropathic pain. [26] The method of treatment according to claim 24 wherein the medical condition comprises epilepsy.
PCT/IB2004/051408 2003-08-05 2004-08-05 Stable sustained release oral dosage form of gabapentin WO2005011666A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN968DE2003 2003-08-05
IN968/DEL/2003 2003-08-05

Publications (1)

Publication Number Publication Date
WO2005011666A1 true WO2005011666A1 (en) 2005-02-10

Family

ID=34113378

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/051408 WO2005011666A1 (en) 2003-08-05 2004-08-05 Stable sustained release oral dosage form of gabapentin

Country Status (2)

Country Link
CN (1) CN1832736A (en)
WO (1) WO2005011666A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006077492A1 (en) * 2005-01-24 2006-07-27 Ranbaxy Laboratories Limited Sustained release oral dosage forms of gabapentin
WO2006113568A2 (en) * 2005-04-19 2006-10-26 Alza Corporation Controlled delivery dosage form of tramadol and gabapentin
KR100715354B1 (en) 2005-08-30 2007-05-08 주식회사 대웅제약 A stable gabapentin formulation suppressing production of impurities and preparation process thereof
WO2007086694A1 (en) * 2006-01-27 2007-08-02 Cj Cheiljedang Corporation Zaltoprofen-containing sustained release tablet and process for the preparation thereof
FR2897267A1 (en) * 2006-02-16 2007-08-17 Flamel Technologies Sa MULTIMICROPARTICULAR PHARMACEUTICAL FORMS FOR PER OS ADMINISTRATION
WO2011042793A1 (en) * 2009-10-06 2011-04-14 Micro Labs Limited Stabilized pharmaceutical composition comprising gabapentin with minimum levels of pharmaceutically acceptable inert excipients
US20150147405A1 (en) * 2012-04-10 2015-05-28 Alpina Laudanum Institute Of Phytopharmaceutical Science Ag Wet granulation process and granulate material comprising arabic gum
US20170216212A1 (en) * 2007-11-23 2017-08-03 Gruenenthal Gmbh Tapentadol compositions

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102688216A (en) * 2012-04-16 2012-09-26 杭州天诚药业有限公司 Gabapentin tablet and preparation method thereof
CN110583654A (en) * 2019-09-18 2019-12-20 北京农学院 Plant source nematicide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294198B1 (en) * 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
US20020091159A1 (en) * 2000-09-26 2002-07-11 Spiridon Spireas Stable solid dosage forms of amino acids and processes for producing same
WO2003103634A1 (en) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Sustained release oral dosage forms of gabapentin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294198B1 (en) * 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
US20030008004A1 (en) * 1999-08-24 2003-01-09 Zalman Vilkov Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
US20020091159A1 (en) * 2000-09-26 2002-07-11 Spiridon Spireas Stable solid dosage forms of amino acids and processes for producing same
WO2003103634A1 (en) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Sustained release oral dosage forms of gabapentin

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006077492A1 (en) * 2005-01-24 2006-07-27 Ranbaxy Laboratories Limited Sustained release oral dosage forms of gabapentin
WO2006113568A2 (en) * 2005-04-19 2006-10-26 Alza Corporation Controlled delivery dosage form of tramadol and gabapentin
WO2006113568A3 (en) * 2005-04-19 2007-04-05 Alza Corp Controlled delivery dosage form of tramadol and gabapentin
KR100715354B1 (en) 2005-08-30 2007-05-08 주식회사 대웅제약 A stable gabapentin formulation suppressing production of impurities and preparation process thereof
WO2007086694A1 (en) * 2006-01-27 2007-08-02 Cj Cheiljedang Corporation Zaltoprofen-containing sustained release tablet and process for the preparation thereof
WO2007093642A2 (en) * 2006-02-16 2007-08-23 Flamel Technologies Microparticulate pharmaceutical forms resistant to immediate release of the active principle in the presence of alcohol
FR2897267A1 (en) * 2006-02-16 2007-08-17 Flamel Technologies Sa MULTIMICROPARTICULAR PHARMACEUTICAL FORMS FOR PER OS ADMINISTRATION
WO2007093642A3 (en) * 2006-02-16 2007-10-04 Flamel Tech Sa Microparticulate pharmaceutical forms resistant to immediate release of the active principle in the presence of alcohol
JP2009526825A (en) * 2006-02-16 2009-07-23 フラメル・テクノロジーズ Multiparticulate pharmaceutical formulation for oral administration
US20170216212A1 (en) * 2007-11-23 2017-08-03 Gruenenthal Gmbh Tapentadol compositions
WO2011042793A1 (en) * 2009-10-06 2011-04-14 Micro Labs Limited Stabilized pharmaceutical composition comprising gabapentin with minimum levels of pharmaceutically acceptable inert excipients
US20150147405A1 (en) * 2012-04-10 2015-05-28 Alpina Laudanum Institute Of Phytopharmaceutical Science Ag Wet granulation process and granulate material comprising arabic gum
US10092518B2 (en) * 2012-04-10 2018-10-09 Alpina Laudanum Institute Of Phytopharmaceutical Sciences Ag Wet granulation process and granulate material comprising Arabic gum

Also Published As

Publication number Publication date
CN1832736A (en) 2006-09-13

Similar Documents

Publication Publication Date Title
US6673369B2 (en) Controlled release formulation
JP4334610B2 (en) Solid pharmaceutical composition containing pregabalin
JPH02209A (en) Control release compound of carbidopa/levodopa
CA2740146A1 (en) Immediate release dosage forms of sodium oxybate
CA2529746A1 (en) Oral extended-release composition
EP2726064B1 (en) Controlled release oral dosage form comprising oxycodone
US20050158380A1 (en) Sustained release oral dosage forms of gabapentin
WO2009066315A2 (en) Sustained release compositions of trimetazidine and process for preparation thereof
WO2004019901A2 (en) Sustained release pharmaceutical composition
BG107372A (en) Sustained-release preparations of quinolone antibiotics and method for preparation thereof
US20040033262A1 (en) Sustained release pharmaceutical composition of a cephalosporin antibiotic
WO2005011666A1 (en) Stable sustained release oral dosage form of gabapentin
WO2005077332A2 (en) Stable sustained-release oral dosage forms of gabapentin and process for preparation thereof
US20060159752A1 (en) Extended release matrix tablets
WO2006123213A1 (en) Modified release formulations of gliclazide
US20060159751A1 (en) Controlled release pharmaceutical compositions of carbidopa and levodopa
WO2009027786A2 (en) Matrix dosage forms of varenicline
WO2006077492A1 (en) Sustained release oral dosage forms of gabapentin
US20050053657A1 (en) Controlled release formulation of clarithromycin or tinidazol
EP2010158B1 (en) Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
WO2005020978A1 (en) Sustained release oral tablets of gabapentin and process for their preparation
KR20160105662A (en) Pharmaceutical composition comprising eperison and pelubiprofen
WO2008032208A2 (en) Extended release formulation of an antiepileptic agent
US20040096496A1 (en) Sustained release pharmaceutical composition of a cephalosporin antibiotic
JP2009525953A (en) Sustained release formulation of divalproic acid and its derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480022497.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1153/DELNP/2006

Country of ref document: IN

122 Ep: pct application non-entry in european phase